UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K/A
(Amendment
No. 1)
[X] |
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the fiscal year ended December 31, 2017
OR
[ ] |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from to
Commission
File Number: 001-38022
MATINAS
BIOPHARMA HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
No.
46-3011414 |
(State
or other jurisdiction of
incorporation
or organization) |
(I.R.S.
Employer
Identification
No.) |
1545
Route 206 South, Suite 302
Bedminster,
New Jersey 07921
(Address
of principal executive offices) (Zip Code)
908-443-1860
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act: None
Title
of Class: |
|
Name
of Each Exchange on Which Registered: |
Common
Stock,
par value $0.0001 |
|
NYSE
American |
Securities
registered pursuant to Section 12(g) of the Act:
None.
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes
[ ] No [X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes
[ ] No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes
[X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes
[X] No [ ]
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Large
accelerated filer |
[ ] |
Accelerated
filer |
[X] |
|
|
|
|
Non-accelerated
filer |
[ ]
(Do not check if a smaller reporting company) |
Smaller
reporting company |
[X] |
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]
The
aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates of the registrant computed
by reference to the price at which the common stock was last sold on June 30, 2017 was approximately $123.1 million.
As
of March 2, 2018 there were 93,478,602 shares of the registrant’s common stock, $0.0001 par value, outstanding.
DOCUMENTS
INCORPORATED BY REFERENCE
None.
EXPLANATORY
NOTE
This
Amendment No. 1 on Form 10-K/A hereby amends the Registrant’s Annual Report on Form 10-K for the fiscal year ended December
31, 2017 (the “Form 10-K”), which the Registrant filed with the Securities and Exchange Commission on March 16, 2018.
This amendment is being filed solely to amend and replace Exhibit 23.1 to the Form 10-K, which inadvertently omitted references
to certain of the Registrant’s registration statements. In addition, pursuant to Rule 13a-14(a) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), we are including with this Amendment No. 1 certain currently
dated certifications. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does
not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. We are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002 as no financial
statements are being filed with this Amendment No. 1.
This
Amendment does not affect any other parts of or exhibits to the Form 10-K, and those unaffected parts or exhibits are not included
in this Amendment. Except as described above, no other portion of the Form 10-K for the fiscal year ended December 31, 2017 is
amended hereby and the Form 10-K continues to speak as of the date of the original filing of the Form 10-K. No modification or
update is otherwise being made to any other disclosure or exhibits to such Form 10-K. Accordingly, this Amendment should be read
in conjunction with such Form 10-K and the Registrant’s filings made with the Securities and Exchange Commission subsequent
to the date of such Form 10-K.
PART
IV
Item
15. |
Exhibits
And Financial Statement Schedules |
Exhibit
No. |
|
Description |
|
|
|
2.1 |
|
Merger
Agreement, dated July 11, 2013, by and among the Company, Matinas Merger Sub, Inc., and Matinas BioPharma, Inc. (incorporated
by reference to Exhibit 2.1 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC
on February 7, 2014). |
|
|
|
2.2 |
|
Agreement
and Plan of Merger (the “Merger Agreement”) with Aquarius Biotechnologies, Inc., a Delaware corporation (“Aquarius”),
Saffron Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”) and
J. Carl Craft, as the stockholder representative (incorporated herein by reference to Exhibit 2.1 to the Company’s Current
Report on Form 8-K filed with the SEC on January 30, 2015). |
|
|
|
3.1 |
|
Certificate
of Incorporation (incorporated by reference to Exhibit 3.1 to Amendment No. 1 to the Company’s Registration Statement
on Form S-1 filed with the SEC on February 7, 2014). |
|
|
|
3.2 |
|
Bylaws
(incorporated by reference to Exhibit 3.2 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed
with the SEC on February 7, 2014). |
4.5 |
|
Form
of 2015 Investor Warrant. (incorporated by reference to Exhibit 4.4 to the post-effective amendment No. 1 to Form S-1 filed
with the SEC on April 17, 2015.) |
|
|
|
4.6 |
|
Form
of 2015 Placement Agent Warrant. (incorporated by reference to Exhibit 4.5 to the post-effective amendment No. 1 to Form S-1
filed with the SEC on April 17, 2015.) |
|
|
|
4.7 |
|
Registration
Rights Agreement dated March 31, 2015 between the Company and the investors named therein. (incorporated by reference to Exhibit
4.6 to the post-effective amendment No. 1 to Form S-1 filed with the SEC on April 17, 2015.) |
|
|
|
4.8 |
|
Form
of 2016 Placement Agent Warrant (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form S-1 filed
with the SEC on November 2, 2016.) |
|
|
|
10.1 |
|
Voting
Agreement, dated July 30, 2013, by and among the Company and the stockholders named therein. (incorporated by reference to
Exhibit 10.5 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7,
2014). |
|
|
|
10.2 |
|
Matinas
BioPharma Holdings, Inc. Amended and Restated 2013 Equity Compensation Plan (incorporated herein by reference to Exhibit 10.6
to the Company’s Annual Report on Form 10-K filed on March 31, 2015.) † |
|
|
|
10.3 |
|
Form
of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Company’s Registration
Statement on Form S-1 filed with the SEC on February 7, 2014). † |
|
|
|
10.4 |
|
Form
of Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.8 to Amendment No. 1 to the Company’s
Registration Statement on Form S-1 filed with the SEC on February 7, 2014). † |
|
|
|
10.9 |
|
Employment
Agreement, dated July 30, 2013, between the Company and Roelof Rongen (incorporated by reference to Exhibit 10.9 to Amendment
No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). † |
10.10 |
|
Employment
Agreement, dated July 30, 2013, between the Company and Abdel A. Fawzy. (incorporated by reference to Exhibit 10.11 to Amendment
No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). † |
|
|
|
10.11 |
|
Employment
Agreement effective as of October 4, 2013 between the Company and Jerome D.
Jabbour (incorporated by reference to Exhibit 10.12 to Amendment No. 1 to the Company’s Registration Statement
on Form S-1 filed with the SEC on February 7, 2014). † |
|
|
|
10.12 |
|
Offer
Letter, dated October 31, 2013, between the Company and Gary Gaglione (incorporated by reference to Exhibit 10.13 to Amendment
No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 7, 2014). † |
|
|
|
10.13 |
|
Form
of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to Amendment No. 1 to the Company’s Registration
Statement on Form S-1 filed with the SEC on February 7, 2014). † |
10.14 |
|
Lease,
effective as of November 4, 2013, by and between the company and A-K Bedminster Associates, L.P. (incorporated by reference
to Exhibit 10.17 to Amendment No. 1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February
7, 2014). |
|
|
|
10.15 |
|
Amended
and Restated Exclusive License Agreement dated as of January 29, 2015, by and between Rutgers, the State University of New
Jersey and Aquarius Biotechnologies, Inc. (incorporated herein by reference to Exhibit 10.18 to the Company’s Annual
Report on Form 10-K filed on March 31, 2015.) +. |
10.16 |
|
Employment
Agreement, dated March 12, 2015, between Matinas BioPharma Holdings, Inc. and Douglas F. Kling. (incorporated herein by reference
to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2015). † |
|
|
|
10.17 |
|
Placement
Agency Agreement dated March 19, 2015 between the Company and Aegis Capital Corp. (incorporated herein by reference to Exhibit
10.20 of the Company’s Registration Statement on Form S-1 (Reg. No. 333-193455), filed with the SEC on April 17, 2015). |
|
|
|
10.18 |
|
Form
of Subscription Agreement for the Company’s 2015 private placement. (incorporated herein by reference to Exhibit 10.21
of the Company’s Registration Statement on Form S-1 (Reg. No. 333-193455), filed with the SEC on April 17, 2015). |
|
|
|
10.19 |
|
Employment
Agreement, dated September 1, 2015, between Matinas Biopharma Holdings, Inc. and Raphael J. Mannino. (incorporated herein
by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 1, 2015). |
|
|
|
10.20 |
|
Separation
and Consulting Agreement between George Bobotas and Matinas BioPharma Holdings, Inc., dated September 29, 2015. (incorporated
herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 1, 2015).
† |
|
|
|
10.21 |
|
Placement
Agency Agreement dated June 27, 2016 by and between Matinas BioPharma Holdings, Inc. and Aegis Captial Corp. (incorporated
by reference to Exhibit 10.21 to the Registration Statement on Form S-1 filed with the SEC on November 2, 2016.) |
|
|
|
10.22 |
|
Finder’s
Agreement dated July 29, 2016 by and between Matinas BioPharma Holdings, Inc. and Aegis Captial Corp. (incorporated by reference
to Exhibit 10.22 to the Registration Statement on Form S-1 filed with the SEC on November 2, 2016.) |
|
|
|
10.23 |
|
Employment
Agreement, dated March 22, 2017, between Matinas Biopharma Holdings, Inc. and Roelof Rongen (incorporated herein by reference
to Exhibit 10.23 to the Company’s Annual Report on Form 10-K filed on March 31, 2017.)† |
|
|
|
10.24 |
|
Employment
Agreement, dated March 22, 2017, between Matinas Biopharma Holdings, Inc. and Abdel Fawzy (incorporated herein by reference
to Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed on March 31, 2017.)† |
|
|
|
10.25 |
|
Lease
Agreement, dated as of December 15, 2016, by and between CIP II/AR Bridgewater Holdings LLC, and Matinas BioPharma Holdings,
Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC
on April 28, 2017) |
|
|
|
10.26 |
|
Employment
Agreement, effective as of April 18, 2017, by and between the Company and Dominick M. DiPaolo (incorporated herein by reference
to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 18, 2017)† |
|
|
|
10.27 |
|
Controlled
Equity OfferingSM Sales Agreement, dated April 28, 2017, by and between Matinas BioPharma Holdings, Inc. and Cantor
Fitzgerald & Co. (incorporated herein by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed
with the SEC on April 28, 2017) |
|
|
|
10.28 |
|
Separation Agreement between Abdel Fawzy and Matinas BioPharma Holdings, Inc., dated January 29, 2018. †** |
|
|
|
21.1 |
|
Subsidiaries Index** |
|
|
|
23.1 |
|
Consent of EisnerAmper LLP* |
|
|
|
31.1 |
|
Certification of President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* |
|
|
|
31.2 |
|
Certification of Acting Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002* |
|
|
|
32.1 |
|
Section 1350 Certifications** |
|
|
|
101 |
|
The
following financial information from the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, formatted
in XBRL (eXtensible Business Reporting Language), is filed electronically herewith: (i) Consolidated Balance Sheets as of
December 31, 2017 and 2015; (ii) Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December
31, 2017 and 2015; (iii) Consolidated Statement of Changes in Stockholders’ Equity (Deficit) for the Years Ended December
31, 2017 and 2015; (iv) Consolidated Statements of Cash Flows for the Years Ended December 31, 2017 and 2015; and (v) Notes
to Consolidated Financial Statements.* |
+ |
Confidential
treatment has been requested for certain provisions of this Exhibit pursuant to Rule 24b-2 promulgated under the Securities
Exchange Act of 1934, as amended. |
† |
Indicates
a management contract or compensation plan, contract or arrangement. |
* |
Filed
herewith. |
** |
Previously
filed.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the city of Bedminster, State of New Jersey on May 25, 2018.
|
MATINAS
BIOPHARMA HOLDINGS, INC. |
|
|
|
|
By: |
/s/Jerome
D. Jabbour |
|
Name: |
Jerome
D. Jabbour
|
|
Title: |
Chief
Executive Officer |
|
|
|
|
By: |
/s/
Gary Gaglione |
|
Name: |
Gary
Gaglione |
|
Title: |
Acting
Chief Financial Officer |
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.
Person |
|
Capacity |
|
Date |
|
|
|
|
|
/s/Jerome
D. Jabbour |
|
Chief
Executive Officer and Director |
|
May
25, 2018 |
Jerome
D. Jabbour |
|
(Principal
Executive Officer) |
|
|
|
|
|
|
|
/s/
Gary Gaglione |
|
Acting
Chief Financial Officer |
|
May
25, 2018 |
Gary
Gaglione |
|
(Principal
Financial and Accounting Officer) |
|
|
|
|
|
|
|
|
|
Chairman
of the Board |
|
|
Herbert
Conrad |
|
|
|
|
|
|
|
|
|
/s/
Matthew A. Wikler |
|
Director |
|
May
25, 2018 |
Matthew
A. Wikler |
|
|
|
|
|
|
|
|
|
/s/
James S. Scibetta |
|
Director |
|
May
25, 2018 |
James
S. Scibetta |
|
|
|
|
|
|
|
|
|
/s/
Adam K. Stern |
|
Director |
|
May
25, 2018 |
Adam
K. Stern |
|
|
|
|
|
|
|
|
|
/s/
Eric Ende |
|
Director |
|
May
25, 2018 |
Eric
Ende |
|
|
|
|